HANDI hopes that you find these resources to be helpful and informative as you or a family member face a major life transition.
Watch this video to learn how copay accumulator adjustments affect patients requiring specialty medications with no generic alternatives.
It's not too late to provide your feedback and help drive the critical direction of inhibitor research. Deadline is November 12th!
In this study, researchers uncovered a relatively high rate of established risk factor amongst young people hemophilia, then discuss possible interventions for prevention.
By accessing this activity healthcare providers will increase their knowledge of the potential role of gene therapy to address challenges in current hemophilia treatment.
Bayer received FDA approval for new extended half-life hemophilia A product for patients 12 yrs and older.
The new vial size will reduce the reconstitution time that was needed to prepare multiple vials for a similar dose.
The therapy is for people with severe and moderately severe hemophilia B.
The therapy in trial is for the prophylactic treatment of individuals with hemophilia A or B with inhibitors.
An interview with one of the recipients of NHF's Innovative Investigator Awards
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car